{
  "nctId": "NCT04003636",
  "briefTitle": "Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)",
  "officialTitle": "A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma",
  "protocolDocument": {
    "nctId": "NCT04003636",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2022-06-16",
    "uploadDate": "2023-12-06T15:43",
    "size": 1127285,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04003636/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "TRIPLE",
  "enrollmentInfo": {
    "enrollmentCount": 1069,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-09-24",
    "completionDate": "2025-04-01",
    "primaryCompletionDate": "2022-12-15",
    "firstSubmitDate": "2019-06-28",
    "firstPostDate": "2019-07-01"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria\n\n* Has histologically confirmed diagnosis of advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer)\n* Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as determined by the site investigator\n* Participants with a history of hepatitis B or hepatitis C can be enrolled if they meet study criteria\n* Is able to provide archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion\n* Has a life expectancy of greater than 3 months\n* Has adequate organ function\n\nExclusion Criteria\n\n* Has had previous systemic therapy for advanced (metastatic) or unresectable (locally advanced) biliary tract cancer (intra-or extra hepatic cholangiocarcinoma or gallbladder cancer)\n* Has ampullary cancer\n* Has small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology and/or mucinous cystic neoplasms\n* Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti- programmed cell death ligand 1 or 2 (anti-PD-L1, anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 \\[CTLA-4\\], OX-40, CD137)\n* Has a known history of, or any evidence of, central nervous system (CNS) metastases and/or carcinomatous meningitis, as assessed by local site investigator\n* Has had an allogenic tissue/solid organ transplant",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Overall Survival (OS)",
        "description": "Overall survival was defined as the time from randomization to death due to any cause.",
        "timeFrame": "Up to approximately 38 months"
      }
    ],
    "secondary": [
      {
        "measure": "Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (BICR)",
        "description": "PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 by BICR, or death due to any cause, whichever occurred first.",
        "timeFrame": "Up to approximately 26 months"
      },
      {
        "measure": "Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)",
        "description": "ORR was defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a â‰¥30% decrease in the sum of diameters \\[SOD\\] of target lesions) as assessed by BICR per RECIST 1.1, which was adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ.",
        "timeFrame": "Up to approximately 26 months"
      },
      {
        "measure": "Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR",
        "description": "For participants who demonstrate a confirmed CR or PR, DOR was the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurred first.",
        "timeFrame": "Up to approximately 38 months"
      },
      {
        "measure": "Number of Participants Who Experience One or More Adverse Events (AE)",
        "description": "An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.",
        "timeFrame": "Up to approximately 38 months"
      },
      {
        "measure": "Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)",
        "description": "An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurs during the course of the study.",
        "timeFrame": "Up to approximately 38 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 0,
      "exclusionCount": 0,
      "totalCount": 0
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 60,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:45.084Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}